Khalifa Kush is expanding into Europe. Starting in early 2025, Khalifa Kush will enter the German medical cannabis market through a strategic multi-year partnership with Berlin-based Sanity Group and its leading medical cannabis brand, avaay Medical.
Beginning in January 2025, avaay will introduce two exclusive Khalifa Kush strains in the form of flower as a medical offering to German patients, with additional strain launches to follow throughout the year. Grown under GACP-certified conditions, these strains were specifically produced for the German market by British Columbia cultivator, Miracle Valley and processed under EU-GMP standards. They will be available in over 3,000 pharmacies throughout the country for licensed patients. This collaboration underscores a shared commitment to delivering high-quality cannabis products, combining Khalifa Kush's renowned expertise and exclusive genetics with avaay Medical's robust market presence and ability to scale.
"I'm excited for our international expansion of Khalifa Kush, as we bring the brand to the European market, starting with Germany," said Wiz Khalifa. "When we started exploring a partnership it was key to find a group in Europe who shares our passion for quality and we found that in Sanity Group."
"Partnering with Khalifa Kush marks a significant milestone for Sanity Group and the German medical cannabis market," said Finn Haensel, CEO and founder of Sanity Group. "As a California-based brand, led by expertise and quality, Khalifa Kush presents an opportunity in Germany to advance patient-centered care, particularly in light of the increased demand for medical cannabis products following the nation's reclassification on April 1."
For more information:
Khalifa Kush